Currently available drug regimens including primaquine and tafenoquine, which target hypnozoites, are not safe for patients who are deficient in glucose-6-phosphate dehydrogenase (G6PD), many of whom live in malaria-endemic areas [6, 7]. This evidence concerns the gene G6PD and malaria.